Morgan Stanley Overweights Avalyn
Morgan Stanley initiates coverage of Avalyn Pharma with overweight rating, citing growth potential. This may impact investor sentiment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.